{"nctId":"NCT00736957","briefTitle":"A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain","startDateStruct":{"date":"2008-05"},"conditions":["Chronic Pain"],"count":219,"armGroups":[{"label":"Tramadol HCL plus Acetaminophen","type":"EXPERIMENTAL","interventionNames":["Drug: Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)"]}],"interventions":[{"name":"Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants whose pain cannot be controlled sufficiently with at least 14-day continuous treatment with identical oral non steroid anti inflammatory drugs (NSAIDs) at a usual maximum dose during 3 months prior to this study\n* Ambulatory participants without need for any supportive device or assistance during daily life\n* Outpatients\n* Participants who do not plan to change the therapeutic policy and content of the medications for underlying disease during screening period to the end of Treatment Period I\n* Sustention of chronic pain due to Osteo Arthritis (OA), Low Back Pain (LBP), Rheumatoid Arthritis (RA), Neck Shoulder Arm Syndrome (NSAS), Diabetic Neuropathy (DN), Post herpetic Neuralgia (PHN) or other for at least 3 months\n\nExclusion Criteria:\n\n* Participants with conditions for which opioids are contraindicated\n* Participants with conditions for which APAP are contraindicated\n* Participants with history of convulsion or the possibility of convulsive seizure\n* Participants with concurrent, previous, or possible alcohol dependence, drug dependence, or narcotic addiction\n* Pregnant Participants or those who may be pregnant, lactating mothers, and Participants who wish pregnancy during the study period.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4","description":"Pain over the last 24 hours was assessed by using VAS score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.80","spread":"11.629"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.28","spread":"21.189"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in VAS24 Score at Week 52","description":"Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.80","spread":"11.629"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.54","spread":"21.936"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement From Baseline in VAS24 Score","description":"Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Intensity Difference (PID) at Week 4","description":"PID is defined as the amount of change in the pain intensity at each evaluation time point (at 2 and 4 hours after the study drug dosing) from the baseline for each participant. Pain Intensity was evaluated on a 4-stage scale ranging from 3=severe pain to 0=no pain. PID ranges from -3 (the worst) to +3 (the most improved).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Pain Relief (PAR) Score at Week 4","description":"Pain relief was evaluated based on a 5-stage scale from 4 (complete relief) to 0 (no relief). An increase in score represented improvement and decrease represented disease progression","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Pain Relief Combined With Pain Intensity Difference (PRID) at Week 4","description":"PRID was sum of the PID and PAR for each participant at each evaluation time point (2 hours after dosing, 4 hours after dosing). Pain Intensity was evaluated on a 4-stage scale ranges from 3=severe pain to 0=no pain and PID ranges from -3 (the worst) to +3 (the most improved). PAR ranges from 0 (no improved) to +4 (the most improved). PRID ranges from -3 (the worst) to +7 (the most improved).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form-36 (SF-36) Score","description":"SF-36 is a metric for general health and Quality of Life (QOL), consists of 8 sub-scale indices related to health and QOL (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health). Each of the sub-scale scores ranged from 0 to 100, where higher values indicate a better health status or a better mental status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":"17.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"9.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"12.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":"15.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"11.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"13.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":"6.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"7.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"8.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":"10.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"7.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"8.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":"9.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"8.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"9.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":"13.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"11.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"11.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":"14.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"12.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"14.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":"11.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"8.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"10.11"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":190},"commonTop":["Nausea","Constipation","Vomiting","Dizziness","Nasopharyngitis"]}}}